First Author: A.Karalezli TURKEY
Co Author(s): S. Sul
Back to previous
To evaluate the outcomes of phacoemulsification combined with ranibizumab in patients with wet age related macular degeneration (AMD).
Department of Ophthalmmology, Muğla Sıtkı Koçman University
The first month outcomes of 14 eyes of patients with wet AMD, who underwent phacoemulsification combined with a single dose of ranibizumab 0.5mg/0.5mL were determined. Pre and postoperative best-spectacle corrected visual acuities (BSCVA) were estimated with Snellen chart and converted to LogMAR. Pre- and postoperative central foveal thicknesses (CFTs), subfoveal choroidal thicknesses (SCTs) and existence of complications related with AMD (increase of subretinal fluid-intraretinal cysts, development of cystoid macular edema) were evaluated with optical coherence tomography (OCT).
All patients underwent uneventful cataract surgery combined with 0.5mg/0.5mL intravitreal ranibizumab injection. At first month, BSCVA significantly improved from 0.9±0.31 LogMAR to 0,32±0.27 LogMAR (p=0.001). CFT significantly decreased from 262±51µ to 205±29µ (p=0.001). SCT significanlty increased from 175±32µ to 195±40µ (p=0.003). There was detected no cystoid macular edema or subretinal fluid at the first month. However, in two patients, intraretinal cysts remained despite the regression of subretinal fluid
SCT which seems to be related with post-surgical inflammation significantly increased despite ranibizumab injection. However, ranibizumab was effective in reducing the intraretinal and subretinal exudations related with active subfoveal neovascularization and controlling the post-surgical retinal inflammation. Cataract surgery combined with ranibizumab injection seemed to be safe and have favourable visual outcomes in patients with wet AMD and cataract.